Literature DB >> 9923909

Antibiotic resistance in Helicobacter pylori.

L Teare, T Peters, S Saverymuttu, R Owen, I Tiwari.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 9923909     DOI： 10.1016/S0140-6736(05)77257-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.

Authors:  Shohreh Farshad; Abdolvahab Alborzi; Aziz Japoni; Reza Ranjbar; Kazem Hosseini Asl; Parisa Badiee; Maneli Amin Shahidi; Marziyeh Hosseini
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

3.  Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome.

Authors:  M E Street; P Caruana; C Caffarelli; W Magliani; M Manfredi; F Fornaroli; G L de'Angelis
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

4.  Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.

Authors:  V Y Miendje Deyi; V Y Miendje Deyi; P Bontems; J Vanderpas; E De Koster; R Ntounda; C Van den Borre; S Cadranel; A Burette
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 5.  Molecular testing for antibiotic resistance in Helicobacter pylori.

Authors:  R J Owen
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 6.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

7.  Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.

Authors:  Josip Bago; Branko Pevec; Monika Tomić; Marinko Marusić; Vinko Bakula; Petra Bago
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

8.  High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial.

Authors:  Petra Bago; Aleksandar Vcev; Monika Tomic; Marjan Rozankovic; Marinko Marusić; Josip Bago
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.